MiNK Therapeutics, Inc..
INKT.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Their primary focus is on engineering and developing iNKT cells to target specif...Show More
Better Health for All
0
No specific, concrete data points or facts were found in the provided articles to assess INKT.US against any of the 'Better Health for All' KPIs. is a press release announcing research presentations, but it does not contain quantitative data or specific outcomes related to health impact, safety, accessibility, investment, or ethical practices.
1
is unavailable, and is irrelevant to INKT.US.
2
Fair Money & Economic Opportunity
0
No evidence available to assess MiNK Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, quantitative data was found in the provided articles for any of the KPIs related to Fair Pay & Worker Respect. The articles provide CEO total compensation but lack median employee compensation to calculate a pay ratio.
1
Employee headcount changes are reported, but not voluntary turnover.
2
Nasdaq listing compliance issues are not considered labor-law or human-rights violations. No information is available regarding living wage coverage, collective bargaining, safety incident rates, pay equity, worker engagement scores, insecure contracts, or health insurance coverage.
3
Fair Trade & Ethical Sourcing
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing for MiNK Therapeutics, Inc. (INKT.US). The articles outline general ethical expectations and codes of conduct for suppliers and internal personnel, but do not provide quantitative evidence regarding fair-trade certification share, supplier audit frequency, substantiated forced or child labor incidents, supply chain traceability coverage, remediation speed for violations, the percentage of supplier contracts with enforceable ethical clauses, materials risk index, or supplier diversity spend.
1
Honest & Fair Business
-30
MiNK Therapeutics received a notice in 2022 regarding a default judgment from the Walloon Region seeking repayment of approximately $2.3 million for allegedly not providing required notification about discontinued research and operations.
1
The company's Corporate Governance Guidelines state that at least a majority of the Board of Directors shall meet Nasdaq independence standards.
2
The Board has determined that five directors are currently independent.
3
The Code of Ethics, adopted in 2021 and updated in 2023, applies to all directors, officers, and employees.
4
The company states that since January 1, 2021, it has not taken any action in violation of the FCPA.
5
KPMG LLP has served as the independent registered public accounting firm since 2020, and the Audit Committee oversees its appointment, independence, and performance.
6
Kind to Animals
0
MiNK Therapeutics conducts pre-clinical studies on animals to assess product safety.
1
However, there is no information available regarding the company's animal testing policy, the volume of animals used, or any investment in animal-free technologies.
2
No data was found on cruelty-free certifications, alternative testing methods, humane certifications for operations, wildlife conservation initiatives, ethical input substitution, supplier audits for welfare compliance, cage-free sourcing, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement related to animal welfare.
3
No War, No Weapons
0
The provided articles do not contain any specific, concrete data points or information relevant to assessing MiNK Therapeutics, Inc. against the 'No War, No Weapons' ethical value. Both article summaries explicitly state that no data pertinent to this value is present.
1
Planet-Friendly Business
0
No specific, concrete data points relevant to the 'Planet-Friendly Business' KPIs were found in the provided articles. The articles primarily focus on financial performance, clinical trial progress, and general business operations, with limited information on environmental metrics such as total emissions, renewable energy use, water consumption per revenue, waste diversion rates, or climate-related targets and initiatives. While one article mentioned energy consumption, water usage, chemical waste, and carbon emission reduction strategies, the data provided did not align with the specific quantitative thresholds or definitions required by the rubric's KPIs (e.g., total emissions, percentage of renewable energy, water use per revenue unit, or waste diversion rate).
1
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles to assess INKT.US against any of the KPIs for the 'Respect for Cultures & Communities' ethical value. The articles primarily contained financial data or information unrelated to the company's community engagement, cultural impact, or related policies and actions.
1
Safe & Smart Tech
0
No evidence available to assess MiNK Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
-40
MiNK Therapeutics has implemented waste reduction initiatives in its laboratory operations, including closed-system cell processing, single-use bioreactors, and green chemistry principles.
1
These efforts have led to a 6.1% reduction in chemical waste.
2
The company also has annual reduction targets for chemical waste, with a specific target of 6.1%.
3